BRIEF-GSK starts Phase III study to evaluate dabrafenib-trametinib combination for melanoma

LONDON Fri Feb 1, 2013 7:06am EST

Related Topics

LONDON Feb 1 (Reuters) - GlaxoSmithKline Plc : * Press release: GlaxoSmithKline starts phase iiistudy to test combined

braf/mek inhibition in patients with braf positivemelanoma following surgery * Primary endpoint of the study is relapse-free survival

FILED UNDER:
Photo

After wave of QE, onus shifts to leaders to boost economy

DAVOS, Switzerland - Central banks have done their best to rescue the world economy by printing money and politicians must now act fast to enact structural reforms and pro-investment policies to boost growth, central bankers said on Saturday.